A Genomic "Roadmap" to "Better" Drugs

Utilization of pharmacogenomic information has the potential to significantly improve treatment outcome and markedly reduce the rate of attrition of drugs in clinical development. A major gap that limits our ability to utilize pharmacogenomic information in drug discovery, drug development or clinic...

Full description

Saved in:
Bibliographic Details
Published in:Drug metabolism reviews 2008-01, Vol.40 (2), p.225-239
Main Authors: Liao, Guochun, Zhang, Xun, Clark, David J., Peltz, Gary
Format: Article
Language:English
Subjects:
Biotransformation - genetics
Computational Biology
Computational Genetics
Drug Design
Drug Monitoring
Drug-Related Side Effects and Adverse Reactions
Genetic Testing
Genetic Variation
Genomics
Genotype
Humans
In silico pharmacogenetics
Patient Selection
Pharmaceutical Preparations - metabolism
Pharmacogenetics
Pharmacogenetics - methods
Phenotype
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Utilization of pharmacogenomic information has the potential to significantly improve treatment outcome and markedly reduce the rate of attrition of drugs in clinical development. A major gap that limits our ability to utilize pharmacogenomic information in drug discovery, drug development or clinical practice is that we often do not know the genetic variants responsible for inter-individual differences in drug metabolism or drug response. We examine emerging genomic methods that can fill this gap; these methods can be used to generate new information about drug metabolism or mechanism of action, or to identify predictors of drug response. Although they have not yet had their full impact, a wider application of these emerging genomic technologies has the potential to significantly improve the safety of drugs, the quality of patient care and the efficiency of clinical drug development.
ISSN:0360-2532
1097-9883
DOI:10.1080/03602530801952815